AIDS-Related Kaposi Sarcoma: MMP inhibitor COL-3 active and well tolerated in AIDS-related Kaposi sarcoma

AIDSWEEKLY Plus; Monday, May 29, 2006
Staff Medical Writers

According to a recently published study from the United States, "Matrix metalloproteinases (MMPs) are involved in tumor metastasis and are overexpressed in Kaposi's sarcoma (KS) cells.

"In a phase I trial of the MMP inhibitor COL-3 in patients with AIDS-related KS, the drug was well tolerated, KS regression was observed, and MMP-2 levels decreased significantly in responders compared with nonresponders. The aim of this trial was to extend these initial observations."

"This was a randomized, parallel-group, phase II study. COL-3 was administered orally once daily at one of two doses (group A received 50 mg and group B received 100 mg) to patients with AIDS-related KS.

"Antiretroviral therapy was permitted but not required. Serial tumor assessments and plasma levels of MMPs were obtained. Study end points were progressive KS and recurrent dose-limiting toxicity," B.J. Dezube and colleagues at Beth Israel Deaconess Medical Center said.

"Seventy-five patients received 137 in group A and 38 in group B. Fifty-seven patients (76%) had received prior KS therapy. Thirty-three patients (44%) had more than 50 KS lesions.

"The response rate in group A was 41%, which was significantly greater than the prespecified target rate of 20% (95% CI 25 to 58%; p=0.003); the response rate of group B was 29% (p=not significant)," investigators reported.

Dezube continued, "There were significant declines in MMP-2 and MMP-9 plasma levels from baseline to minimum value with treatment (MMP-2, p<0.001; MMP-9, p=0.001). The most common adverse events were photosensitivity and rash."

"COL-3 when administered as 50 mg/day," concluded the authors, "is both active and well tolerated in the treatment of AIDS-related KS. COL-3 is a promising agent for the treatment of this opportunistic neoplasm of AIDS."

Dezube and colleagues published their study in the Journal of Clinical Oncology (Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS malignancy consortium study. J Clin Oncol. 2006 Mar 20;24(9):1389-94.).

For more information, contact B.J. Dezube, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, CC-913, Boston, MA 02215, USA.

Publisher contact information for the Journal of Clinical Oncology is: American Society Clinical Oncology, 330 John Carlyle St., Ste. 300, Alexandria, VA 22314, USA.

Keywords: Boston, Massachusetts, United States, HIV/AIDS, Kaposi Sarcoma, Matrix Metalloproteinase Inhibitor, COL-3, Safety & Efficacy.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Dezube BJ, Krown SE, Lee JY, et al., "Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study", J Clin Oncol. 2006 Mar 20;24(9):1389-94..

PubMED Related articles Search

2006-05-29
AW060513

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.